Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet
The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Profound Medical (PROF) Just Flashed Golden Cross Signal: Do You Buy?
Profound Medical (PROF) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PROF's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Profound Medical (PROF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock?
Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade
The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.38 per share a year ago.
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Arun Swarup Menawat - Chairman of the Board & CEO Mathieu Burtnyk - President Rashed Dewan - Chief Financial Officer Stephen Kilmer - Corporate Participant Investor Relations - Corporate Participant Thomas Tamberrino - Chief Commercial Officer Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division Douglas W. Loe - Leede Financial Inc., Research Division John Glenn McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Michael W.
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.28 per share a year ago.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2025 Financial Results Conference Call.
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago.
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Stephen Kilmer – IR Rashed Dewan - CFO Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat – CEO Conference Call Participants John Baugh - Stifel Michael Freeman - Raymond James Operator Thank you for standing by and welcome to the Profound Medical Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
